Lupin inks pact to acquire two inhalation brands from Sunovion for USD 75 mn
indiatimes.com
science
2022-10-20 05:30:00

Headquartered in Mumbai, Lupin develops and commercialises a wide range of branded and generic formulations.Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol. The Mumbai-based firm expects the transaction to be accretive to earnings in the first year.
